Carcinoma, Mucoepidermoid
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
Drugs by status
Phase 2 trials (15)
Phase 1 trials (24)
- metformin
- 7-hydroxystaurosporine
- allogeneic natural killer cells
- alvespimycin
- irinotecan
- temsirolimus
- valproic acid
- fluorouracil
- tacrolimus
- paclitaxel
- photochlor
- hydroxyurea
- trastuzumab
- proflavine
- methylene blue
- carboplatin
- interleukin-12
- cyclophosphamide
- everolimus
- autologous monocyte-derived dendritic cells transfected with dna
- etoposide
- sargramostim
- psma car-t cell
- vrp-encapsulated sarna encoding il-12
Other trials (4)
Organizations
Organization Involved with Phase 2 Indications (7)
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (2)